Aravive Investor Presentation Deck

Upcoming Key Milestones Initiate 20mg/kg cohort of PDAC Study Safety and Preliminary Activity from P2 ccRCC Trial Complete Enrollment of P3 PROC 2H 2022 P3 PROC Top Line Results Additional P2 ccRCC Trial Data Initiation of P3 ccRCC mid 2023 Submit BLA for PROC, if trial successful Updated PDAC Data 2H 2023 Potential Approval of PROC BLA Updated PDAC and ccRCC Data 1H 2024 *Depends on mature data from P1b PDAC study 36

View entire presentation